新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 礼来 » 礼来勃林格糖尿病药物empagliflozin三期临床结果积极

礼来勃林格糖尿病药物empagliflozin三期临床结果积极

来源:生物谷 2013-01-08 14:00

2013年1月8日讯 /生物谷BIOON/ --礼来和勃林格殷格翰表示,其糖尿病药物empagliflozin在四项Ⅲ期临床研究结果达到了主要的疗效指标,每天服用剂量为10mg和25mg的患者与服用安慰剂的患者相比,其糖化血红蛋白水平相较于基线值有明显变化。

Empagliflozin属于新型化合物类别,即SGLT-2抑制剂中的一种。(生物谷Bioon.com)

英文报道:

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced top-line results for four completed Phase III clinical trials for empagliflozin, an investigational sodium glucose co-transporter-2 (SGLT-2) inhibitor being studied for treatment of patients with type 2 diabetes (T2D). In all four studies, the primary efficacy endpoint, defined as significant change in HbA1c from baseline compared to placebo, was met with empagliflozin (10 and 25 mg) taken once daily.

These four pivotal studies from the empagliflozin trial program are:

Study 1245.20 (n=986) evaluated 10 mg and 25 mg doses of empagliflozin as monotherapy versus placebo for 24 weeks. 1
Study 1245.23 (n=1,504) compared 10 mg and 25 mg doses of empagliflozin as an add-on to metformin and metformin plus sulfonylurea versus placebo for 24 weeks. 1
Study 1245.19 (n=499) assessed 10 mg and 25 mg doses of empagliflozin as an add-on to pioglitazone and pioglitazone plus metformin versus placebo for 24 weeks. 1
Study 1245.36 (n=741) evaluated 25 mg dose of empagliflozin in patients with type 2 diabetes with mild, moderate or severe renal impairment, and 10 mg dose in those with mild renal impairment versus placebo for 52 weeks. 1
Incidence of adverse events was similar for placebo, empagliflozin 10mg and 25mg. Genital infections occurred more often with empagliflozin (both dosages) compared with placebo. This safety information is consistent with findings reported in the Phase II study results for empagliflozin.2

Empagliflozin is part of a class of drugs being investigated for the reduction of blood glucose levels in adults with T2D. In clinical trials to date, SGLT-2 inhibitors have been shown to reduce blood glucose.

“Boehringer Ingelheim and Lilly are encouraged by the efficacy and safety results for empagliflozin,” said Prof. Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim. “Many patients with type 2 diabetes are not meeting their blood sugar level goals, and alternative treatment options are needed for them. We believe we are now one step closer to bringing a new treatment option to these patients.”

“We are pleased with the results for these Phase III clinical trials for empagliflozin,” said Enrique Conterno, President, Lilly Diabetes. “Diabetes is growing at a tremendous rate across the world. Patients and their physicians need more treatment options in order to help improve their blood sugar levels and reach their treatment goals.”

Empagliflozin is being investigated in adults with T2D in a Phase III clinical trial program that will enroll over 14,500 patients.1 In total, this program comprises eight multinational clinical trials, including a large cardiovascular outcome trial.

The pivotal studies for empagliflozin completed in 2012, and Boehringer Ingelheim and Lilly anticipate filing for regulatory review in the U.S., Europe and Japan in 2013. Boehringer Ingelheim and Lilly plan to present detailed data disclosures for many of these studies at scientific medical meetings and publications in 2013 and 2014.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库